<p><strong>SAN MATEO</strong> &#8212; <a href="https://cts.businesswire.com/ct/CT?id=smartlink&;url=https%3A%2F%2Fwww.curvebio.com%2F&;esheet=54344930&;newsitemid=20251029166983&;lan=en-US&;anchor=Curve+Biosciences&;index=1&;md5=0bf43aa552414d62ac706aadaf2c5d21" target="_blank" rel="nofollow noopener" shape="rect">Curve Biosciences</a>, a company developing a Whole-Body Intelligence perform to monitor diseases, has raised $40 million in funding led by Luma Group with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and others.</p>
<p>The funding will advance the clinical validation and commercialization of Curve’s Whole-Body Intelligence platform to transform chronic disease monitoring.</p>
<p>Curve has created the first molecular blueprint of the human body with the company’s Whole-Body Atlas — the world’s largest collection of manually curated tissue samples characterized by organ and disease state. By returning to tissue-level biological truth, the company is creating simple, proactive Whole-Body Blood Tests that anticipate chronic disease, guide treatment, and align patients, insurers, pharma, and doctors.</p>
<p>“Chronic diseases are on the rise, and healthcare costs are skyrocketing as a result. We need to improve patient monitoring to realize the positive impacts of breakthroughs like GLP-1s,” said Ritish Patnaik, PhD, CEO and Co-Founder, Curve Biosciences. “To raise the standard of chronic disease monitoring, we are now introducing the first Whole-Body Intelligence platform with AI models trained on our Whole-Body Atlas and fueled by our Whole-Body Blood Tests. We’ve paired this platform with a successful executive team to realize our vision for proactive, personalized chronic care that minimizes suffering.”</p>
<p>Curve’s executive team includes:</p>
<ul class="bwlistdisc">
<li>Ritish Patnaik, PhD, Chief Executive Officer – Former business development at Genentech, with deep expertise in AI, data engineering and precision testing.</li>
<li>Nathan Hunkapiller, PhD, Chief Scientific Officer – Previously Head of R&;D at Natera and Head of R&;D at GRAIL, where he led the development of advanced blood tests for oncology, prenatal screening and hereditary cancer screening.</li>
<li>Alice Chen, PhD, Chief Operating Officer – Former Head of Product and Program Management at GRAIL, where she led strategy for a multi-cancer early detection blood test, after leadership roles at Natera, Progyny and Sienna Biopharmaceuticals.</li>
<li>Chuba Oyolu, PhD, Chief Technology Officer – Founding Scientist and Senior Site Director at Counsyl, where he led the automation, delivery, and scaling of advanced blood tests for prenatal screening and hereditary cancer screening.</li>
<li>Prof. Shan Wang, PhD, Chief Innovation Officer and Scientific Founder – Leland T. Edwards Professor in the School of Engineering at Stanford University with 300+ publications and 70+ issued or pending patents over his 30+ year academic career.</li>
</ul>
<p>“We believe Curve’s Whole-Body Intelligence platform represents the next frontier in clinical testing, with the potential to fundamentally reshape how we monitor and manage chronic disease,” said<b> </b>Themasap Khan, PhD, Co-Founder and Partner, Luma Group. “By anchoring in human tissue data, Curve is building a clinically actionable platform with clear reimbursement potential and massive market applicability.”</p>

SAN FRANCISCO -- Deepgram, a Voice AI platform, has raised $130 million in Series C…
Walmart Inc. is teaming with Google to launch a new experience that brings AI from…
SAN MATEO -- EpiBiologics, which specializes in tissue-selective extracellular protein degradation, has announced the completion…
Sandisk announced SANDISK Optimus as the new name for its internal SSD lineup for gamers,…
Meta has made deals with three companies — Oklo, Terrapower and Vistra — that will…
MENLO PARK -- Orca Bio, a late-stage biotechnology company committed to transforming the lives of…